Molecure Future Growth
Future criteria checks 2/6
Molecure's earnings are forecast to decline at 6.3% per annum while its annual revenue is expected to grow at 62.2% per year. EPS is expected to decline by 4.9% per annum.
Key information
-6.3%
Earnings growth rate
-4.9%
EPS growth rate
| Pharmaceuticals earnings growth | 14.2% |
| Revenue growth rate | 62.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Jan 2024 |
Recent future growth updates
No updates
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 16 | -24 | N/A | -8 | 1 |
| 12/31/2024 | 53 | 0 | N/A | 31 | 1 |
| 12/31/2023 | 2 | -17 | N/A | -15 | 1 |
| 9/30/2023 | 1 | -17 | -52 | -8 | N/A |
| 6/30/2023 | 1 | -16 | -38 | -2 | N/A |
| 3/31/2023 | 2 | -15 | -47 | -12 | N/A |
| 12/31/2022 | 2 | -15 | -44 | -10 | N/A |
| 9/30/2022 | 2 | -16 | -36 | -8 | N/A |
| 6/30/2022 | 2 | -16 | -38 | -14 | N/A |
| 3/31/2022 | 2 | -15 | -37 | -15 | N/A |
| 12/31/2021 | 1 | -14 | -32 | -13 | N/A |
| 9/30/2021 | 124 | 63 | 63 | 47 | N/A |
| 6/30/2021 | 124 | 64 | 62 | 47 | N/A |
| 3/31/2021 | 125 | 67 | 67 | 56 | N/A |
| 12/31/2020 | 125 | 68 | 66 | 57 | N/A |
| 9/30/2020 | 2 | -3 | -31 | -2 | N/A |
| 6/30/2020 | 2 | -3 | -32 | -2 | N/A |
| 3/31/2020 | 2 | -4 | -38 | -6 | N/A |
| 12/31/2019 | 2 | -4 | -42 | -7 | N/A |
| 9/30/2019 | 2 | -5 | -43 | -4 | N/A |
| 6/30/2019 | 2 | -5 | -41 | -6 | N/A |
| 3/31/2019 | 1 | -5 | -36 | -4 | N/A |
| 12/31/2018 | 1 | -4 | -32 | -5 | N/A |
| 9/30/2018 | 1 | -4 | -28 | -5 | N/A |
| 6/30/2018 | 2 | -4 | -26 | -2 | N/A |
| 3/31/2018 | 2 | -2 | -26 | -2 | N/A |
| 12/31/2017 | 1 | -2 | -25 | -1 | N/A |
| 9/30/2017 | 1 | -3 | -23 | -5 | N/A |
| 6/30/2017 | 1 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2016 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 1 | -1 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MOC's revenue (62.2% per year) is forecast to grow faster than the Polish market (4.3% per year).
High Growth Revenue: MOC's revenue (62.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MOC's Return on Equity is forecast to be high in 3 years time